Licensed Agreement with F. Hoffmann-La Roche Ltd.
History
History
Our Journey
1996
Installation, Qualification & Validation
1999 - 2000
2001 - 2002
Process validation, stability studies
Commercial Production Started.
2002
2005
Agreement signed with NOVARTIS for contract manufacturing.
Launched Cephalosporin products from a dedicated facility.
2009
2010
Launch cream & ointment products from separate facility.
Established a state-of-the-art facility for Small Volume Parenteral, Ophthalmic, Lyophilized, and Biosimilar products.
2012
2013
Established Metered Dose Inhaler (MDI) facility.
Marketing & Distribution agreement with MSD Pharmaceutical, subsidiary of Merck.
2015
2016
Anti-cancer products launch from HPL dedicated oncology facility.
Distribution agreement signed with ELI LILLY
2019
2019
Sergel became number one pharmaceutical brand in Bangladesh
HPL achieved TGA EU GMP certification for oral solids
2019
2020
Started dedicated sterile cephalosporin facility
Launched hormone products from HPL dedicated facility
2021
2023
Launched HPL's first product in USA
HPL achieved EU GMP certification for anti-cancer products.